Literature DB >> 1380059

Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens.

E Baixeras1, B Huard, C Miossec, S Jitsukawa, M Martin, T Hercend, C Auffray, F Triebel, D Piatier-Tonneau.   

Abstract

The lymphocyte activation gene 3 (LAG-3), expressed in human activated T and natural killer (NK) cells, is closely related to CD4 at the gene and protein levels. We report here the initial characterization of the LAG-3-encoded protein. We have generated two monoclonal antibodies after immunization of mice with a 30-amino acid peptide that corresponds to an exposed extra loop region present in the LAG-3 immunoglobulin-like first domain. The reactivity of these reagents is directed against LAG-3 since they recognize both membrane-expressed and soluble recombinant LAG-3 molecules produced in a baculovirus expression system. The two antibodies are likely to react with the same or closely related epitope (termed LAG-3.1) exposed on the LAG-3 first domain extra loop, as assessed in competition experiments on LAG-3-expressing activated lymphocytes. Cellular distribution analysis indicated that the LAG-3.1 epitope is expressed on activated T (both CD4+ and CD8+ subsets) and NK cells, and not on activated B cells or monocytes. In immunoprecipitation experiments performed on activated T and NK cell lysates, a 70-kD protein was detected after SDS-PAGE analysis. 45-kD protein species were also immunoprecipitated. Both the 70- and 45-kD proteins were shown to be N-glycosylated. In Western blot analysis, only the former molecule was recognized by the anti-LAG-3 antibodies, demonstrating that it is LAG-3 encoded. These anti-LAG-3 antibodies were used to investigate whether the LAG-3 protein interacts with the CD4 ligands. By using a high-level expression cellular system based on COS-7 cell transfection with recombinant CDM8 vectors and a quantitative cellular adhesion assay, we demonstrate that rosette formation between LAG-3-transfected COS-7 cells and human leukocyte antigen (HLA) class II-bearing B lymphocytes is specifically dependent on LAG-3/HLA class II interaction. In contrast to CD4, LAG-3 does not bind the human immunodeficiency virus gp120. This initial characterization will guide further studies on the functions of this molecule, which may play an important role in immune responses mediated by T and NK lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380059      PMCID: PMC2119326          DOI: 10.1084/jem.176.2.327

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  42 in total

1.  Regulation of T helper-B lymphocyte adhesion through CD4-HLA class II interaction.

Authors:  F Mazerolles; F Amblard; C Lumbroso; O Lecomte; P F Van de Moortele; C Barbat; D Piatier-Tonneau; C Auffray; A Fischer
Journal:  Eur J Immunol       Date:  1990-03       Impact factor: 5.532

2.  Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding.

Authors:  L K Clayton; M Sieh; D A Pious; E L Reinherz
Journal:  Nature       Date:  1989-06-15       Impact factor: 49.962

3.  Inhibition by anti-HLA class II monoclonal antibodies of monocyte-dependent T cell proliferation induced by monoclonal antibody OKT3.

Authors:  G Ruggiero; C Manzo; S Fontana; G Scala; G Pirozzi; S Ferrone; S Zappacosta
Journal:  Eur J Immunol       Date:  1987-11       Impact factor: 5.532

Review 4.  Structural diversity in domains of the immunoglobulin superfamily.

Authors:  A F Williams; S J Davis; Q He; A N Barclay
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1989

5.  Cloned human CD3- lymphocytes with natural killer-like activity do not express nor rearrange T cell receptor gamma genes.

Authors:  F Triebel; M Graziani; F Faure; S Jitsukawa; T Hercend
Journal:  Eur J Immunol       Date:  1987-08       Impact factor: 5.532

6.  Cloning and expression of a lymphocyte activation gene (LAG-1).

Authors:  E Baixeras; S Roman-Roman; S Jitsukawa; C Genevee; S Mechiche; E Viegas-Pequignot; T Hercend; F Triebel
Journal:  Mol Immunol       Date:  1990-11       Impact factor: 4.407

7.  Human B cell variants immunoselected against a single Ia antigen subset have lost expression of several Ia antigen subsets.

Authors:  R S Accolla
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

8.  LAG-3, a novel lymphocyte activation gene closely related to CD4.

Authors:  F Triebel; S Jitsukawa; E Baixeras; S Roman-Roman; C Genevee; E Viegas-Pequignot; T Hercend
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

9.  Human TCR-gamma+/delta+, CD8+ T lymphocytes recognize tetanus toxoid in an MHC-restricted fashion.

Authors:  D Kozbor; G Trinchieri; D S Monos; M Isobe; G Russo; J A Haney; C Zmijewski; C M Croce
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

10.  Class II MHC molecules and the HIV gp 120 envelope protein interact with functionally distinct regions of the CD4 molecule.

Authors:  D Lamarre; D J Capon; D R Karp; T Gregory; E O Long; R P Sékaly
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

View more
  125 in total

1.  Attributes of gammadelta intraepithelial lymphocytes as suggested by their transcriptional profile.

Authors:  A M Fahrer; Y Konigshofer; E M Kerr; G Ghandour; D H Mack; M M Davis; Y H Chien
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

Review 2.  Update on hepatitis C virus-specific immunity.

Authors:  Donatella Ciuffreda; Arthur Y Kim
Journal:  Curr Opin HIV AIDS       Date:  2011-11       Impact factor: 4.283

3.  Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

Authors:  Christine I Chen; P Leif Bergsagel; Harminder Paul; Wei Xu; Anthea Lau; Nimisha Dave; Vishal Kukreti; Ellen Wei; Chungyee Leung-Hagesteijn; Zhi Hua Li; Joseph Brandwein; Mariela Pantoja; James Johnston; Spencer Gibson; Tiffany Hernandez; David Spaner; Suzanne Trudel
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

Review 4.  Costimulatory and coinhibitory receptors in anti-tumor immunity.

Authors:  Gregory Driessens; Justin Kline; Thomas F Gajewski
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

5.  Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand.

Authors:  B Huard; P Gaulard; F Faure; T Hercend; F Triebel
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

6.  Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Authors:  Douglas B Johnson; Mellissa J Nixon; Yu Wang; Daniel Y Wang; Emily Castellanos; Monica V Estrada; Paula I Ericsson-Gonzalez; Candace H Cote; Roberto Salgado; Violeta Sanchez; Phillip T Dean; Susan R Opalenik; Daniel M Schreeder; David L Rimm; Ju Young Kim; Jennifer Bordeaux; Sherene Loi; Leora Horn; Melinda E Sanders; P Brent Ferrell; Yaomin Xu; Jeffrey A Sosman; Randall S Davis; Justin M Balko
Journal:  JCI Insight       Date:  2018-12-20

Review 7.  Immunotherapy for brain cancer: recent progress and future promise.

Authors:  Christopher M Jackson; Michael Lim; Charles G Drake
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

Review 8.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

9.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

Authors:  Shawn D Blackburn; Haina Shin; W Nicholas Haining; Tao Zou; Creg J Workman; Antonio Polley; Michael R Betts; Gordon J Freeman; Dario A A Vignali; E John Wherry
Journal:  Nat Immunol       Date:  2008-11-30       Impact factor: 25.606

Review 10.  How do regulatory T cells work?

Authors:  A Corthay
Journal:  Scand J Immunol       Date:  2009-10       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.